TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Sutro Biopharma
Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors

Sutro Biopharma initiated a Phase 1 clinical trial for STRO-004, a next-generation antibody-drug conjugate targeting tissue factor in various solid tumors. The trial aims to evaluate safety, pharmacokinetics, and preliminary anti-tumor activity across multiple cancer types.

Insights
DANOY   positive

Listed among key market players in a rapidly expanding infant nutrition sector


STRO   positive

Company is advancing innovative cancer treatment technology, initiating a promising clinical trial for a novel therapeutic approach with potential to address unmet medical needs